One of the immunological features of IBM is the presence of autoantibodies targeting cytosolic 5′-nucleotidase 1A (cN1A), reported in 33–80% of patients [3,4,5,6,7,8]. This evidence concerns the gene NT5C1A and inclusion body myositis.